Percutaneous Aponeurotomy in the Treatment of Dupuytren's Disease

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Summary

The efficiency of percutaneous aponeurotomy in the treatment of Dupuytrens disease is well known. However, the duration of the clinical improvement after aponeurotomy is not well known. This study aims primarily at measuring the incidence rate of local relapse of Dupuytrens-induced finger flessum, within two years following treatment by percutaneous aponeurotomy in Dupuytrens.

See also
	Status	Clinical Trial	Phase
	Recruiting	`NCT02301078` - Short-term Function and Pain After Treatment for Dupuytren's Disease	N/A

NCT number	NCT02474576
Study type	Interventional
Source	Groupe Hospitalier Diaconesses Croix Saint-Simon
Contact
Status	Completed
Phase	N/A
Start date	September 2015
Completion date	April 2020

Percutaneous Aponeurotomy in the Treatment of Dupuytren's Disease — APADUP

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms